World Wires · story 9600 · unverified · 1 source(s)

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Kailera today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program.

Open in the desk

Coverage

• Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection GlobeNewswire: public companies · tier D · clear net · 2026-09-30 11:00 UTC

What this site indexes